https://mabwell-therapeutics.com/mabwell-therapeutics-announces-publication-of-preclinical-data-on-differentiated-trem2-agonist-antibody-03o05-in-journal-of-neuroinflammation/ 2026-05-04T23:42:40+00:00 https://mabwell-therapeutics.com/mabwell-therapeutics-receives-fda-ind-clearance-to-initiate-clinical-trials-for-mwtx-4611-to-treat-alzheimers-disease/ 2025-10-07T18:44:43+00:00 https://mabwell-therapeutics.com/mabwell-therapeutics-announces-first-patient-dosed-in-u-s-phase-ii-study-of-mwtx-003-disc-3405/ 2025-09-30T16:27:33+00:00 https://mabwell-therapeutics.com/mabwell-therapeutics-receives-fda-ind-clearance-to-initiate-clinical-trials-for-mwtx-003-9mw3011-to-treat-iron-related-rare-diseases/ 2025-05-05T13:36:01+00:00 https://mabwell-therapeutics.com/mabwell-presents-first-in-human-clinical-data-of-mwtx-003-9mw3011-at-eha-2024/ 2025-04-14T13:37:13+00:00 https://mabwell-therapeutics.com/fda-grants-orphan-drug-designation-to-mwtx-003-disc-3405-for-the-treatment-of-polycythemia-vera/ 2025-04-14T13:33:43+00:00 https://mabwell-therapeutics.com/fda-grants-fast-track-designation-to-mwtx-003-for-polycythemia-vera/ 2025-04-14T13:32:09+00:00 https://mabwell-therapeutics.com/mabwell-therapeutics-presents-preclinical-data-on-novel-anti-amyloid-beta-oligomer-antibody-at-aaic-2023/ 2025-04-14T13:30:42+00:00 https://mabwell-therapeutics.com/mabwell-doses-first-subject-in-first-in-human-trial-of-mwtx-003-9mw3011/ 2025-04-14T13:29:44+00:00 https://mabwell-therapeutics.com/mabwell-therapeutics-announces-exclusive-licensing-agreement-with-disc-medicine-for-novel-hematologic-drug-candidates/ 2025-04-14T13:29:35+00:00 https://mabwell-therapeutics.com/mabwell-therapeutics-receives-china-nmpa-approval-to-initiate-clinical-trials-for-mwtx-003-9mw3011-injection-2/ 2025-04-14T13:29:26+00:00